| sess_SDA_2026_04_26_ | What are the key molecular mechanisms by which gut microbiome dysbiosis drives n | 1.00 | 4 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gut-brain-pd-ffdff6f4 |
| sess_SDA-2026-04-26- | What are the mechanisms by which microglial senescence contributes to ALS pathol | 0.75 | 4 | 6 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260425215446 |
| sess_SDA-2026-04-26- | Blood-brain barrier permeability changes as early biomarkers for neurodegenerati | 0.50 | 0 | 7 | completed | 2026-04-26 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| sess_SDA-2026-04-25- | Do connectivity motifs predict which cell types in a neurodegenerative mouse mod | 0.50 | 0 | 4 | completed | 2026-04-26 | SDA-2026-04-25-allen-zeng-connectivity-vulnerability-circuit |
| sess_SDA-2026-04-25- | Microglial senescence in Alzheimer and Parkinson disease progression | 0.50 | 0 | 6 | completed | 2026-04-26 | SDA-2026-04-25-gap-20260425234323 |
| paper_debate_paper-3 | What are the scientific significance and neurodegeneration implications of: Anta | 0.72 | 3 | 4 | completed | 2026-04-26 | |
| paper_debate_paper-4 | What are the scientific significance and neurodegeneration implications of: Tau | 0.72 | 4 | 4 | completed | 2026-04-26 | |
| paper_debate_paper-3 | What are the scientific significance and neurodegeneration implications of: Beyo | 0.72 | 3 | 4 | completed | 2026-04-26 | |
| sess_SDA-2026-04-25- | Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration | 0.50 | 0 | 5 | completed | 2026-04-26 | SDA-2026-04-25-gap-epi-clock-biomarker-20260425-222549 |
| sess-gap-pubmed-2026 | What are the optimal oxygen pressure, duration, and frequency parameters for HBO | 0.68 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| sess-gap-pubmed-2026 | What mechanisms drive the self-amplifying vicious cycle linking oxidative stress | 0.84 | 6 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181140-0af1a353-debate |
| sess-gap-pubmed-2026 | Does restoring neuronal AMPK activity reverse microglial inflammation in vivo? | 0.77 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-180918-962b1ada-debate |
| sess-gap-pubmed-2026 | Can ferroptosis inhibitors prevent BBB disruption and edema formation after card | 0.73 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| sess-gap-pubmed-2026 | Which specific factors in conditioned medium from healthy astrocytes rescue moto | 0.65 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-170057-a2f72fd8-debate |
| sess-gap-pubmed-2026 | Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other | 0.66 | 8 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate |
| sess-gap-pubmed-2026 | How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what | 0.66 | 5 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| sess-gap-pubmed-2026 | Which specific CSF molecular components are essential for maintaining disease-re | 0.66 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-081644-1d2624b8-debate |
| sess-gap-pubmed-2026 | Which specific transcription factors mediate MAPT suppression during proteostati | 0.66 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-083749-7d0cea3d-debate |
| sess-gap-pubmed-2026 | What specific autophagy pathways are defective in radiation-induced pericyte sen | 0.66 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-193006-9525a13b-debate |
| sess-gap-pubmed-2026 | How does parthenolide specifically modulate ADORA2A signaling to produce antidep | 0.66 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-193037-1dc5e03a-debate |
| sess-gap-pubmed-2026 | What is the molecular mechanism by which rutin inhibits tau aggregation and olig | 0.66 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-085530-9015d285-debate |
| sess-gap-pubmed-2026 | Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i | 0.54 | 5 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-145520-5692b02e-debate |
| sess_gap-pubmed-2026 | What is the minimum effective dose of trazodone required for disease-modifying e | 0.64 | 6 | 4 | completed | 2026-04-26 | |
| sess_gap-debate-2026 | Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ | 0.69 | 7 | 4 | completed | 2026-04-25 | |
| sess_SDA-2026-04-25- | Does tau dendritic missorting persist independently after Aβ clearance, maintain | 0.65 | 7 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-98a600b3ed |
| sess_SDA-2026-04-25- | Does pericyte senescence drive BBB breakdown or result from neurodegeneration as | 0.68 | 6 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-de5dfc4391 |
| sess_SDA-2026-04-25- | What determines the temporal sequence of cholinergic dysfunction versus amyloid/ | 0.65 | 7 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-e849205bca |
| sess_SDA-2026-04-25- | Does C1q function differ based on subcellular localization or binding partner id | 0.68 | 6 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-afba1a80bd |
| sess_SDA-2026-04-25- | Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects | 0.63 | 6 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-18cce7b525 |
| sess_SDA-2026-04-25- | Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate bas | 0.74 | 5 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-9180363b7c |
| sess_SDA-2026-04-25- | Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retenti | 0.58 | 6 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-f4c8357045 |
| sess_aging-mouse-bra | How does gene expression change across age groups (young/middle/old) in hippocam | 1.00 | 3 | 4 | completed | 2026-04-24 | aging-mouse-brain-2026-04-02 |
| pan_0b9f67e3 | is the amyloid cascade hypothesis still important | 0.50 | 0 | 0 | completed | 2026-04-24 | |
| pan_5d0f52d1 | Is the amyloid hypothesis still tractable for AD? | 0.50 | 0 | 0 | completed | 2026-04-24 | |
| sess_hyp_h-b2aeabb1_ | Should PEA-PPARA endocannabinoid signaling be prioritized as a therapeutic strat | 0.76 | 0 | 4 | completed | 2026-04-23 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| sess_hyp_SDA-2026-04 | Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to | 0.81 | 0 | 4 | completed | 2026-04-23 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| target_debate_t-2a37 | Should MAPT (None) be prioritized as a therapeutic target for neurodegeneration? | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should PIEZO1ANDKCNK2 (PIEZO1ANDKCNK2) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CELL-TYPE-SPECIFICESSENTIALGENES (CELL-TYPE-SPECIFICESSENTIALGENES) be pr | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SIRT3 (NAD-dependent deacetylase sirtuin-3, mitochondrial) be prioritized | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should AADC (Aromatic L-amino acid decarboxylase) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CHRNA7 (CHRNA7 Protein) be prioritized as a therapeutic target for neurod | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should GPR109A (Hydroxycarboxylic Acid Receptor 2 (HCAR2)) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MAP6 (Microtubule-associated protein 6) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should GFAP (Glial fibrillary acidic protein) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should ST3GAL2 (ST3 beta-galactoside alpha-2,3-sialyltransferase 2) be prioritiz | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MTOR (Mechanistic Target of Rapamycin) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CSGA (CSGA Protein) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CNO (Cappuccino) be prioritized as a therapeutic target for neurodegenera | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CHMP4B (Charged multivesicular body protein 4B) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-23 | |